Brand-name · Dual GLP-1 / GIP receptor agonist (tirzepatide)

Mounjaro®

A once-weekly tirzepatide injection FDA-approved for type 2 diabetes. Activates both GIP and GLP-1 receptors to improve glycemic control and reduce appetite.

Starting at$1,249.99/mo

Check If I Qualify Read the FAQs

Form

Pre-filled injection pen

Frequency

Once weekly

Drug class

Dual GLP-1 / GIP receptor agonist (tirzepatide)

Who is a candidate for this medication?

Adults 18+ with type 2 diabetes needing improved glycemic control.

Who this medication is not for

Personal or family history of medullary thyroid cancer or MEN 2.
Pregnancy, planning pregnancy, or breastfeeding.
Type 1 diabetes.

Dosage overview

Phase	Dose
Weeks 1–4	2.5 mg once weekly (starter).
Titration	Increased no faster than every 4 weeks up to 15 mg based on response.

Side effects to know about

Common

· Nausea
· Diarrhea
· Decreased appetite
· Vomiting

Serious (call your doctor)

· Pancreatitis
· Gallbladder disease
· Kidney injury
· Severe GI reactions

How your care is monitored

A1c, weight, and side effects each visit.
Hydration and renal function review as indicated.

Pricing

Mounjaro® starts at $1,249.99/mo. No insurance required. HSA/FSA eligible. Cancel anytime.

Common questions

How is Mounjaro different from Zepbound?

Same active ingredient (tirzepatide) and same manufacturer (Eli Lilly). Mounjaro is approved for type 2 diabetes; Zepbound for chronic weight management.